Nevertheless, our research provides additional evidence that inhibiting ATR sensitises a range of patient-derived glioblastoma cell lines to standard treatment and thus this approach is worthy of pursuing with ATR inhibitors that do penetrate the brain. This evidence concerns the gene ATR and glioblastoma.